Literature DB >> 21688169

Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome.

Xiaobo Shi1, Lingyan Zhang, Shuxin Fu, Na Li.   

Abstract

OBJECTIVE: To investigate psychological distress, serum levels of monoamine neurotransmitters and their metabolites, as well as their correlation with polycystic ovarian syndrome (PCOS).
METHODS: Thirty infertility patients with PCOS were assigned as the experimental group and 30 infertility patients without PCOS were assigned as the control group. Psychological distress was self-evaluated in all patients with Symptom Checklist 90 (SCL-90). Serum concentrations of norepinephrine (NE) and its metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxytryptamine (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA), dopamine (DA) and its metabolites homovanillic acid (HVA) and dihydroxy-phenyl acetic acid (DOPAC) were measured by high-performance liquid chromatography.
RESULTS: The anxious and depressive subscales of SCL-90 were significantly higher in infertility patients with PCOS than those without PCOS (p < 0.05). The serum concentrations of 5-HT, 5-HIAA and HVA were significantly lower in infertility patients with PCOS than those without PCOS (p < 0.05). Importantly, the phobia subscale scores of SCL-90 positively correlated with serum MHPG level (p < 0.05), while the hostility subscale's scores negatively correlated with serum DOPAC level (p < 0.05).
CONCLUSION: Psychological and neurological factors play a crucial role in PCOS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688169     DOI: 10.1007/s00404-011-1947-1

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  9 in total

Review 1.  Depression and Anxiety in Polycystic Ovary Syndrome: Etiology and Treatment.

Authors:  Laura G Cooney; Anuja Dokras
Journal:  Curr Psychiatry Rep       Date:  2017-09-20       Impact factor: 5.285

Review 2.  Polycystic Ovary Syndrome, Affective Symptoms, and Neuroactive Steroids: a Focus on Allopregnanolone.

Authors:  Lindsay R Standeven; Elizabeth Olson; Nicole Leistikow; Jennifer L Payne; Lauren M Osborne; Liisa Hantsoo
Journal:  Curr Psychiatry Rep       Date:  2021-04-21       Impact factor: 5.285

Review 3.  Positive Effects of α-Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome.

Authors:  Vincenzo Cardinale; Elisa Lepore; Sabrina Basciani; Salvatore Artale; Maurizio Nordio; Mariano Bizzarri; Vittorio Unfer
Journal:  Nutrients       Date:  2022-08-06       Impact factor: 6.706

Review 4.  Depression in polycystic ovary syndrome: Focusing on pathogenesis and treatment.

Authors:  Liwei Xing; Jinlong Xu; Yuanyuan Wei; Yang Chen; Haina Zhuang; Wei Tang; Shun Yu; Junbao Zhang; Guochen Yin; Ruirui Wang; Rong Zhao; Dongdong Qin
Journal:  Front Psychiatry       Date:  2022-08-31       Impact factor: 5.435

5.  Polycystic ovary syndrome and postpartum depression among Hispanics and non-Hispanics: a population-based study.

Authors:  Adriele D Fugal; Joseph B Stanford; Erica B Johnstone; Kebba Kah; Karen C Schliep
Journal:  AJOG Glob Rep       Date:  2022-07-07

6.  GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile.

Authors:  Nirja Chaudhari; Mitali Dawalbhakta; Laxmipriya Nampoothiri
Journal:  Reprod Biol Endocrinol       Date:  2018-04-11       Impact factor: 5.211

Review 7.  Polycystic Ovary Syndrome: A Brain Disorder Characterized by Eating Problems Originating during Puberty and Adolescence.

Authors:  Régine P M Steegers-Theunissen; Rosalieke E Wiegel; Pauline W Jansen; Joop S E Laven; Kevin D Sinclair
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

8.  Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial.

Authors:  Mina Amiri; Fatemeh Nahidi; Razieh Bidhendi Yarandi; Davood Khalili; Maryam Tohidi; Fahimeh Ramezani Tehrani
Journal:  Health Qual Life Outcomes       Date:  2020-08-31       Impact factor: 3.186

9.  Troxerutin protects against DHT-induced polycystic ovary syndrome in rats.

Authors:  Zixuan Gao; Xiaochen Ma; Jing Liu; Yuhang Ge; Lei Wang; Ping Fu; Zhian Liu; Ruiqin Yao; Xiaonan Yan
Journal:  J Ovarian Res       Date:  2020-09-13       Impact factor: 4.234

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.